Leads Biolabs Announces Partner Oblenio Bio Doses First Patients in Phase 1a Trial of LBL‑051 for Refractory Autoimmune Diseases

-- First‑in‑human trial of Oblenio’s sole asset, a CD19×BCMA×CD3 tri‑specific T‑cell engager, moves forward to rapidly generate broad proof of concept -- -- First‑in‑human trial of Oblenio’s sole asset, a CD19×BCMA×CD3 tri‑specific T‑cell engager, moves forward to rapidly generate broad proof of concept --

Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.